Open AccessUse of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
Author(s) -
Gentille Cesar,
Sarfraz Humaira,
Joshi Jitesh,
Randhawa Jasleen,
Shah Shilpan,
Pingali Sai Ravi
Publication year - 2022
Publication title -
cancer reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 5
ISSN - 2573-8348
DOI - 10.1002/cnr2.1581
Subject(s) - ifosfamide , brentuximab vedotin , romidepsin , etoposide , carboplatin , medicine , oncology , peripheral t cell lymphoma , cd30 , anaplastic large cell lymphoma , lymphoma , chemotherapy , immunology , t cell , chemistry , cisplatin , immune system , histone deacetylase , gene , histone , biochemistry
Background Relapsed/refractory peripheral T‐cell lymphoma (R/R PTCL) has a poor prognosis. Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL. Aim We report outcomes of Bv‐ICE in CD30 (+) and Ro‐ICE in CD30 (−) R/R PTCL treated in “Blinded for peer review” Cancer Center. Methods and Results We retrospectively identified R/R PTCL patients treated with BV‐ICE or romidepsin‐ICE from May 2016 to September 2019. Out of 13 R/R PTCL patients, 6 were treated with Bv‐ICE and 7 with Ro‐ICE. Bv‐ICE had an overall response rate (ORR) of 66.7%, with all the patients achieving a complete response. ORR was 71.4% for Ro‐ICE with 57.1% of patients achieving a complete response. Two patients treated with Bv‐ICE and three treated with Ro‐ICE received transplantation. Conclusion In our experience, treatment with Bv‐ICE and Ro‐ICE based on CD30 positivity is feasible and effective to treat patients with R/R PTCL.